Hemostemix Inc (HEM) - Total Liabilities
Based on the latest financial reports, Hemostemix Inc (HEM) has total liabilities worth CA$4.80 Million CAD (≈ $3.47 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Hemostemix Inc to assess how effectively this company generates cash.
Hemostemix Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Hemostemix Inc's total liabilities have evolved over time, based on quarterly financial data. Check Hemostemix Inc (HEM) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Hemostemix Inc Competitors by Total Liabilities
The table below lists competitors of Hemostemix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avalon Holdings Corporation
NYSE MKT:AWX
|
USA | $53.32 Million |
|
Oceancash Pacific Bhd
KLSE:0049
|
Malaysia | RM29.64 Million |
|
Inter-Delta Tbk
JK:INTD
|
Indonesia | Rp3.69 Billion |
|
Garovaglio y Zorraquin S.A.
BA:GARO
|
Argentina | AR$41.64 Billion |
|
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
|
France | €19.91 Million |
|
LabGenomics Co. Ltd
KQ:084650
|
Korea | ₩76.00 Billion |
|
Axiom Properties Ltd
AU:AXI
|
Australia | AU$6.62 Million |
|
Pharmacielo Ltd
V:PCLO
|
Canada | CA$23.57 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Hemostemix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hemostemix Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hemostemix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hemostemix Inc (2013–2024)
The table below shows the annual total liabilities of Hemostemix Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$8.20 Million ≈ $5.93 Million |
+6.65% |
| 2023-12-31 | CA$7.68 Million ≈ $5.56 Million |
+6.23% |
| 2022-12-31 | CA$7.23 Million ≈ $5.23 Million |
+23.73% |
| 2021-12-31 | CA$5.85 Million ≈ $4.23 Million |
+70.87% |
| 2020-12-31 | CA$3.42 Million ≈ $2.48 Million |
-17.54% |
| 2019-12-31 | CA$4.15 Million ≈ $3.00 Million |
+253.31% |
| 2018-12-31 | CA$1.17 Million ≈ $849.58K |
+152.68% |
| 2017-12-31 | CA$464.79K ≈ $336.22K |
-87.40% |
| 2016-12-31 | CA$3.69 Million ≈ $2.67 Million |
+492.45% |
| 2015-12-31 | CA$622.73K ≈ $450.47K |
+12.87% |
| 2014-12-31 | CA$551.70K ≈ $399.09K |
+127.05% |
| 2013-12-31 | CA$242.98K ≈ $175.77K |
-- |
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more